(13-141) Efficacy of 3 mg Versus 6 mg Rasburicase in the Prevention of Tumor Lysis Syndrome

Wednesday, December 10, 2025

3:15 PM - 4:15 PM

Location: Bayside A, Level 1

Residency Program: CHRISTUS Spohn Shoreline
Residency Program Type: PGY1 (Pharmacy)
Residency Program Location: Texas

Co-Author(s): Claude Holley, Jason Mazour, Gynree Roach, Hannah Hodges

Primary Author(s)